DENTAL-MONITORING/LOUM
5.5.2020 19:50:04 CEST | Business Wire | Press release
Dental Monitoring has acquired Loum, "the digital assistant for patients and healthcare professionals.” Founded in 2017, Loum's objective is to ensure that patients perceive their healthcare positively, and not as a burden. Their innovative developments, in particular an application designed to improve the patient experience, complements Dental Monitoring’s expansive suite of AI-driven tools. The app implements a playful and dynamic system that facilitates the doctor-patient relationship and allows patients to engage fully with their treatment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200505005871/en/
"We are delighted with the acquisition of Loum, which allows us to integrate complementary skills into our teams and meet the expectations of patients and their doctors worldwide. We are coordinating a robust solution and collaborating with a team of skilled colleagues who will enhance our AI-powered platform with new strategies and an innovative approach. Ultimately, we want to design a more playful version of our patient application, and through Loum’s gamification approach, which allows for careful monitoring of treatment, this is an angle that we are now addressing," says Philippe Salah, CEO of the Dental Monitoring.
"Placing gaming at the heart of the healthcare protocol not only brings a little lightness to the patient’s journey, but also makes any follow-up care much more appealing, accessible, and more likely to be followed,” explains Michaël Sutter, CEO of Loum.
"Joining Dental Monitoring is great news for us and our customers. We now offer them the possibility of benefitting from a broader range of cutting-edge solutions for the management of their patients’ care, while continuing to provide them with personalized and local support. This integration is also an accelerator in terms of innovation and is therefore in line with a product offering that remains at the forefront of market expectations. We are delighted to bring our vision of the patient journey and to partner with those who share our taste for service and excellence," announced Michaël Sutter, CEO, and Clément Coicault, COO of Loum.
###
About Dental Monitoring:
Founded in 2015 by Philippe Salah, Dental Monitoring is the first AI-based company to target dental professionals and improve the care they provide their patients.
Dental Monitoring solutions are created to assist dental professionals throughout their patients’ journeys by:
● Simplifying the connection between dental professionals and patients
● Facilitating follow-ups and providing an easier virtual experience during treatment
● Improving treatment stability and results over time
Dental Monitoring is present across Europe, the United States and Asia Pacific. It has 250 employees and 5 offices (Paris, Austin - Texas, London, Hong Kong and Sydney).
Dental Monitoring is changing the way dental and orthodontic professionals care for patients. If you would like more information about Loum and this acquisition, or about the Dental Monitoring’s full suite of tele dentistry solutions, please visit www.dental-monitoring.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200505005871/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease30.6.2026 07:00:00 CEST | Press release
Hengrui Pharma, a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique EyeSol® water-free platform technology, announce today that on June 23, 2026, the China National Medical Products Administration (NMPA) has approved Heng Yi® (0.1% cyclosporine ophthalmic solution) for the treatment of patients with dry eye disease, aiming to increase tear secretion in patients with reduced tear production and improve the sign of the disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629052295/en/ Heng Yi Heng Yi® is the first and only water-free 0.1% cyclosporine ophthalmic solution and the second dry eye disease drug product approved in China based on the EyeSol® platform technology, following the approval of Heng Qin® (perfluorohexyloctane ophthalmic solution) in 202
Nebex Raises $30M Seed Round Led by GV to Build Market Infrastructure for the Global Space Economy29.6.2026 17:38:00 CEST | Press release
The new funding and banking relationship allow Nebex to scale the market and unlock the commercial space economy. Nebex, the market infrastructure platform for the global space economy, announced a $30M seed investment led by GV (Google Ventures), with participation from other top-tier venture funds. The company also announced a banking relationship with J.P. Morgan. The capital raise and new banking relationship will help Nebex scale its platform and connect sovereign space programs with the founders and companies building new technologies to serve the space industry. "We built Nebex because we've seen firsthand that ambitious space founders struggle to deliver complex sovereign programs due to the lack of capital markets infrastructure that supports revenue and cashflow. This is something that exists in nearly every other industry," said Tejpaul Bhatia, CEO of Nebex. "Support from these organizations gives Nebex the additional leverage and financial infrastructure to build the global
Medisca Enters Its Next Chapter Under Founder Antonio Dos Santos29.6.2026 16:19:00 CEST | Press release
Medisca today announced that Founder and Chairman Antonio Dos Santos has returned to the role of Chief Executive Officer as the company enters its next chapter of growth. For more than 35 years, Dos Santos has helped shape Medisca into a global leader in pharmaceutical compounding. As Chief Executive Officer, he will lead the company's long-term strategy, with a focus on expanding Medisca's global reach, investing in new areas of growth, strengthening strategic partnerships, and continuing to advance the products, services, education, and expertise that healthcare professionals rely on every day. "When I founded Medisca, my vision was to raise the standard of pharmaceutical compounding by bringing pharmaceutical-grade quality to the industry and giving healthcare professionals access to the products, knowledge, and innovation they needed to deliver better patient care," said Antonio Dos Santos, Founder and Chief Executive Officer of Medisca. "That purpose continues to guide us. As we b
The Premier Jumping League (PJL) & McCarthy Jumping Team Announce Landmark Purchase29.6.2026 15:10:00 CEST | Press release
With $50 Million Team Acquisition, McCarthy Jumping Team Becomes First PJL Ownership Group Acquisition illustrates strong investor confidence in the future of professional showjumping as highly anticipated 2027 inaugural season to feature 16 teams competing across 14 international events The Premier Jumping League (PJL) today announced that seasoned trader, investor, and competitive race car driver Jason McCarthy and McCarthy Jumping League LLC acquired the first PJL team in a landmark $50 million acquisition, building on rising momentum for the highly acclaimed professional jumping league. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629512997/en/ The Premier Jumping League (PJL), photographed by Daniel Benson. The milestone investment represents an unprecedented valuation for a team in a newly established sports competition and underscores the confidence that sophisticated investors are placing in the PJL. The inaugur
InvestEco Sustainable Food Fund IV Holds a Final Close With Total Commitments of C$106M29.6.2026 15:00:00 CEST | Press release
InvestEco Capital is pleased to announce the final close of the InvestEco Sustainable Food Fund IV. This fund will continue InvestEco’s work of investing in high-growth food companies that promote health and sustainability in the food sector. The Fund closed with total commitments of C$106M, the largest InvestEco fund to date. Investors include Farm Credit Canada, Export Development Canada, Business Development Bank of Canada, Fonds de solidarité FTQ, and two Government of Canada Social Finance Fund wholesalers: Boann and Realize Capital Partners. In addition, the Fund received commitments from a number of private investors and family offices. The Fund's investments to date include Humble Snacks, Little Sesame, Mid-Day Squares and Algae Cooking Club. The Fund expects to make a further 6 - 10 investments over the next few years. InvestEco Capital, founded in 2002, is a Toronto-based venture capital firm and impact investor focused on the sustainable food sector. For more information, em
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom